AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2578-8965/084
1University Department of Gynecology Obstetrics, Donka national Hospital, Conakry Guinea
2University Department of Gynecology Obstetrics, Ignace Deen national Hospital, Conakry Guinea
*Corresponding Author: Tudor Calistru, University of Medicine and Pharmacy, Gr.T. Popa” Doctoral School Department, No. 16 University Street, Iasi, Romania.
Citation: Anton E., Doroftei B., Ilea C., Mariana B., Nicolaiciuc D., Maftei R., Simionescu G., Calistru T., Carmen R. Anton (2020) New therapeutic challenges in metastatic breast cancer: the association of CDK4 / 6 inhibitors with radiotherapy. A short review J. Obstetrics Gynecology and Reproductive Sciences 4(4); DOI: 10.31579/2578-8965/084
Copyright: © 2020, Tudor Calistru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 14 August 2020 | Accepted: 24 August 2020 | Published: 30 August 2020
Keywords: CDK4/6; metastatic breast cancer; radiotherapy
FDA approval of CDK4 / 6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) for metastatic and advanced breast cancer, in combination or not with Fulvestrant or Letrozole, has improved the prognosis of this type of patient population. Palliative radiotherapy with antalgic purpose in most of the cases is often part of the multidisciplinary treatment of bone involvement metastatic breast cancer. In the context of the approval of these innovative therapies and of the development of radiotherapy techniques, including stereotactic radiosurgery, it is necessary to identify the best therapeutic sequence and parameters (dose, volume, fraction size) to obtain a synergistic effect. Considering the toxicity profiles of new therapies (especially lymphopenia and neutropenia) and the different mechanisms of the induction of these toxicities towards radiotherapy and chemotherapy, it is also necessary to demonstrate the safety profile of concomitant or sequential irradiation with the administration of CDK4 / 6 inhibitors in combination with radiation therapy.
Breast cancer is the most common type of female malignancy. Worldwide cancer mortality in women remains high despite the achievements made in diagnosis and treatment. Breast cancer genome sequencing has identified five distinct molecular subtypes, including luminal A, luminal B, human epidermal growth factor receptor (HER2), basal and low claudin, luminal subtypes are characterized by the typical expression of the estrogen receptor (ER) and / or the progesterone receptor (PR), providing the opportunity for hormonal and andocrine therapy. Intrinsic resistance or tolerance to hormone therapy is a cause of treatment failure in this subtype of tumors. Basal-like breast cancer, characterized by the relatively aggressive and absent phenotype of ER, PR, and HER2, also requires the identification of therapy therapies for enhancing prognosis. Following pre-clinical studies, cyclin-dependent kinase inhibitors 4/6 (CDK4 / 6) (Palbociclib, Ribociclib, and Abemaciclib) were approved in combination with aromatase inhibitors (AI) or fulvestrant for metastatic breast cancer (MBC) [1].
The cyclin-dependent family of kinases (CDKs) are regulators of cell cycle progression and cyclin D is a transcriptional target of the estrogen receptor (ER) and its interaction with CDK4 / 6 modulates through the retinoblastoma gene (Rb) the passage of cells from G1 to S phase. Three innovative molecules: Palbociclib (Ibrance, Pfizer, New York, USA), Ribociclib (Kisquali, Novartis, Basel, Switzerland) and Abemaciclib (Verzenio, Eli Lilly, Indianapolis, (ribociclib) were evaluated in the PALOMA (palbociclib), MONALEESA (ribociclib) and MONARCH (abemaciclib) studies in metastatic breast cancer [2].
Palbociclib is the first of the (CDK 4/6) inhibitors, approved in association with endocrine therapy, for patients with advanced breast cancer progressing on endocrine therapy after evaluation of the PALOMA-3 trial. PALOMA-3 randomly assigned 521 patients with advanced HER2-negative breast cancer with hormone receptor positive after disease progression in 2:1 endocrine treatment to receive fulvestrant at 500 mg plus 125 mg / day of palbociceb every three weeks or placebo. The median follow-up was 44.8 months and the results showed an improvement in overall survival by 6.9 months by the addition of palbociceb to fulvestrant compared to fulvestrant alone. [3]
Ribociclib has been approved as a treatment for postmenopausal women with advanced HER2-negative or metastatic HR + breast cancer in combination with an aromatase inhibitor as initial endocrine therapy. The FDA has further expanded the indication for Ribociclib in combination with an AI for pre- / perimenopausal with HER2-negative or metastatic breast cancer as endocrine initial therapy. Ribociclib was approved in combination with fulvestrant for postmenopausal women with HER2-negative or metastatic breast cancer as initial endocrine-based therapy or following disease progression on endocrine therapy. The initial approval of Ribociclib was based on MONALEESA-7, a randomized, double-blind, placebo-controlled trial. The results of the trial estimated a median progression-free survival of 27.5 months for patients in the ribociclib arm versus 13.8 months for those in the placebo arm.
The efficacy of ribocycline in combination with fulvestrant was demonstrated in MONALEESA-3, a double-blind, randomized, placebo-controlled, ribociclib-plus fulvestrant combination study in 726 postmenopausal women with HR-positive, HER2-negative, The estimated mean progression-free survival was 20.5 months for patients who were treated with ribocilib as compared to 12.8 months for placebo arm. The most common adverse effects included neutropenia, nausea, infection, fatigue, diarrhea, leucopenia, vomiting, alopecia, headache, and constipation, rash and cough [4]. Abemaciclib was approved in combination with an aromatase inhibitor as the initial endocrine therapy for postmenopausal women with HER2 + advanced or metastatic breast cancer. The approval was based on the MONARCH 3 trial, a double-blind, placebo-controlled, multicenter randomized (2: 1) study in postmenopausal women with HR +, HER2-negative or metastatic breast cancer. A total of 493 patients were randomized to receive either 150 mg abemaciclib or placebo orally twice daily plus letrozole or anastrozole. The prognostic median progression free survival (PSF), was 28.2 months for patients who received abemaciclib and 14.8 months for the placebo arm. The most common side effects were diarrhea, neutropenia, fatigue, infections, nausea, vomiting, abdominal pain, anemia, and leucopenia [5].
Radiotherapy is used in stages I-III of breast cancer as adjuvant therapy following surgery to improve prognosis, but is in the metastatic settings is used for symptom palliation. Understanding the mechanisms of interaction between radiation and modern systemic therapies introduced into the metastic stage breast cancer such as chemotherapy, immunotherapy, molecular target therapies is the subject of preclinical studies designed in order to maximize the effect of radiotherapy association with systemic therapy with a limited toxicity profile. Following radiotherapy ablative doses, the release of tumor antigens, tumor DNA, cytokines and chemokines promotes intratumoral immunity. Immunomodulatory treatments, such as immune checkpoint inhibitors, could be associated with irradiation to amplify the immune antitumor response in an attempt to improve results in patients with metastatic disease. [6]
The concept of oligometastatic disease resulted in a change in treatment goals for patients diagnosed with metastatic breast cancer with a limited disease. "Oligometastases," is defined as a limited metastasis, involving one to five lesions scattered in a single site or in a reduced number of sites. It has been demonstrated that patients with <5 metastases, aggressively treated, have a better prognosis than those with> 5 metastases treated with surgical excision or radiosurgery ablation. The oligometstatic breast cancer treated with a mulimodal protocol with currative intent has an increased chances of disease control [7].
With the introduction of CDK4 / 6 inhibitors into the spectrum of systemic therapies, the problem of the association of these treatments with palliative radiotherapy or stereotactic radiotherapy for oligometastatic disease has been raised. Clinical trials demonstrating the feasibility of concomitant treatments are limited. Meattini and collaborates report a batch of 5 patients treated with RT with palliation concurrently with ribociclib plus letrozole as a first-line treatment for MBC at the Radiation Oncology Unit of Florence University [8].
Sixteen MBC patients were included in a study and were treated with CDK4 / 6 inhibitors concomitantly with radiotherapy (RT). Thirteen patients (81.3%) received palbociclib, and three patients (18.7%) patients received ribociclib concomitant with RT. 68.7% received palliative radiotherapy in the bones sites (median dose 30Gy, range 8-36Gy), and five patients (31.2%) were treated at higher doses for oligo-metastatic sites (median dose = 50 Gy, interval 39.6-60 Gy). Neutropenia was common (Grade 2 = 12.5%, Grade 3 = 25%, and Grade 4 = 6.3%). The authors conclude that concomitant treatment of CDK4 / 6 and radiotherapy seems to be well tolerated but an increased rate of toxicity, particularly neutropenia was observed [9].
The most common haematological abnormalities observed with CDK4 / 6 inhibitors are not complicated (febrile neutropenia rate is reduced) and can be managed relatively easy by dose adjustments. Cytopenias are less common with abemaciclib, although fatigue and gastrointestinal toxicity are more common associated with this treatment. This could be an argument for the choice of abemaciclib in patients at high risk for neutropenia or who have a large part of the hematogenic marrow contained in the irradiation field. Also palbociclib and ribociclib could be preferred in case of irradiation of bone metastases in vicinity of small bowel in oder to reduce digestive toxicity [10, 11].
Cowdhary et al. included patients who received RT for symptomatic metastases concurrently or within 14 days of palbociceb. Four patients received palbociceb prior to RT (25.0%), 5 concomitantly (31.3%) and 7 after RT (43.8%). The median interval from the closest use of palbocice at RT was 5 days (range, 0-14). 11 patients were irradiated palliative on sites in the axial skeleton, 4 patients were irradiated on the pelvis and pelvis, and 3 patients received RT on the extremities. Pain reduction was performed in all patients and all degrees of hematological toxicity, except for 2 (grade 2), were of grade 1. The authors conclude that the use of association between RT and palbociclib is associated with grades 1 to 2 and no grade 3+ haematological toxicity [12].
CDK4 / 6 inhibitors are now part of MBC management and association with stereotactic ablative radiotherapy for oligometastatic disease but also with palliative radiotherapy become more common. Taking into account the toxicity profile of new therapies, it is necessary to identify the optimal treatment sequence to obtain the best therapeutic response. Preclinical studies are needed to demonstrate the theoretical concepts based on cell-pathway pathways on the association of CDK4 / 6 with radiotherapy and to facilitate translation of these therapies in daily clinical practice.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
